“Surely each new therapy, in addition to being an additional weapon to meet the needs and requirements of people with haemophilia, also represents a tool for doctors who can thus personalize the treatment for each patient. Personalization is a standard we, as a patient association, aim for in an age where we have more treatment options available. This innovative product therefore represents an undoubted advantage for all patients, because it helps to improve their lifestyle. “Thus Cristina Cassone, president of FedemoFederation of Haemophilic Associations, regarding the new efmoroctocog alfa therapy available for patients with haemophilia A..
“The availability of new generation drugs – adds Cassone – will allow us to lengthen the interval between one infusion and the next, improve prophylaxis and quality of life. Where there will be the possibility of infusing the therapy with longer intervals, and thus giving greater protection by preventing bleeding, a better quality of life will be offered not only to patients, but also to their families and caregivers “.
#Cassone #Fedemo #haemophilia #therapy #personalized #treatment